Arachnoiditis from Myelography with Iopamidol, Metrizamide, and Iocarmate Compared in the Animal Model
V M Haughton, Khang‐Cheng Ho
Abstract
V M Haughton, Khang‐Cheng Ho
Abstract
A new aqueous myelographic contrast media, iopamidol, was compared to iocarmate and metrizamide with respect to the risk of arachnoiditis. Macaque monkeys underwent myelography with one of the three contrast media. Twelve weeks later, the animals were restudied with myelography, then sacrificed for histologic studies of the arachnoid. Results suggest that iopamidol is safer than iocarmate and equivalent to metrizamide with respect to the risk of arachnoiditis.
OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A new aqueous myelographic contrast media, iopamidol, was compared to iocarmate and metrizamide with respect to the risk of arachnoiditis. Macaque monkeys underwent myelography with one of the three contrast media. Twelve weeks later, the animals were restudied with myelography, then sacrificed for histologic studies of the arachnoid. Results suggest that iopamidol is safer than iocarmate and equivalent to metrizamide with respect to the risk of arachnoiditis.
Key concepts: Metrizamide, Iopamidol, Arachnoiditis, Myelography, Medicine, Contrast medium, Intrathecal, Radiology